Loading…
Meta‐analysis: reduction in hepatic events following interferon‐alfa therapy of chronic hepatitis B
Aliment Pharmacol Ther 2010; 32: 1059–1068 Summary Background The long‐term benefit of interferon‐alfa (IFN‐α) treatment in preventing various hepatic complications is not certain. Aim To study the effects of IFN‐α on reducing the risk of developing overall hepatic events (hepatocellular carcinoma...
Saved in:
| Published in: | Alimentary pharmacology & therapeutics 2010-11, Vol.32 (9), p.1059-1068 |
|---|---|
| Main Authors: | , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c4307-b869ad6259c0127779f1e1a3d1240dbed270f5a18feca3dadb3883247a141b773 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c4307-b869ad6259c0127779f1e1a3d1240dbed270f5a18feca3dadb3883247a141b773 |
| container_end_page | 1068 |
| container_issue | 9 |
| container_start_page | 1059 |
| container_title | Alimentary pharmacology & therapeutics |
| container_volume | 32 |
| creator | Wong, G. L.‐H. Yiu, K. K.‐L. Wong, V. W.‐S. Tsoi, K. K.‐F. Chan, H. L.‐Y. |
| description | Aliment Pharmacol Ther 2010; 32: 1059–1068
Summary
Background The long‐term benefit of interferon‐alfa (IFN‐α) treatment in preventing various hepatic complications is not certain.
Aim To study the effects of IFN‐α on reducing the risk of developing overall hepatic events (hepatocellular carcinoma, cirrhotic complications and liver‐related mortality) in chronic hepatitis B patients.
Methods Randomized controlled trials, case–control studies and cohort studies were retrieved from electronic databases and conference s. Relative risks (RRs) of different hepatic complications among patients treated by IFN‐α vs. no treatment or placebo were studied.
Results Eleven studies were identified totalling 975 patients treated by IFN‐α vs. 1147 untreated controls for analysis. Patients were treated by IFN‐α for 1–24 months with a post‐treatment follow‐up of 1–13 years. Treatment by IFN‐α reduced the risk of overall hepatic events (RR 0.55, 95% confident interval or CI 0.43–0.70, P |
| doi_str_mv | 10.1111/j.1365-2036.2010.04447.x |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_762285515</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>762285515</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4307-b869ad6259c0127779f1e1a3d1240dbed270f5a18feca3dadb3883247a141b773</originalsourceid><addsrcrecordid>eNqNkcFOGzEURa2qqATaX6i8QV1N-mzP2E6lLigqFAlEF3RteTzPxNFkJtiTQnb9BL6RL8FDAt3ija37zrWtewmhDKYsr6-LKROyKjgIOeWQVSjLUk3v35HJ6-A9mQCXs4JrJvbJQUoLAJAK-Aeyz0GD4kxOyM0lDvbx34PtbLtJIX2jEZu1G0Lf0dDROa7sEBzFv9gNifq-bfu70N3k2YDRY-y70dx6S4c5Rrva0N5TN896dm3dQ0j0x0ey522b8NNuPyR_Tn9en_wqLq7Ozk-OLwpXClBFreXMNpJXMweMK6VmniGzomG8hKbGhivwlWXao8uqbWqhteClsqxktVLikHzZ3ruK_e0a02CWITlsW9thv05GSc51VbHqbSTjEjKpt6SLfUoRvVnFsLRxYxiYsQ-zMGPsZozdjH2Y5z7MfbZ-3j2yrpfYvBpfCsjA0Q6wyeUco-1cSP85wbWuuM7c9y13F1rcvPkD5vj39XgST76BqHY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>762281260</pqid></control><display><type>article</type><title>Meta‐analysis: reduction in hepatic events following interferon‐alfa therapy of chronic hepatitis B</title><source>Wiley-Blackwell Read & Publish Collection</source><creator>Wong, G. L.‐H. ; Yiu, K. K.‐L. ; Wong, V. W.‐S. ; Tsoi, K. K.‐F. ; Chan, H. L.‐Y.</creator><creatorcontrib>Wong, G. L.‐H. ; Yiu, K. K.‐L. ; Wong, V. W.‐S. ; Tsoi, K. K.‐F. ; Chan, H. L.‐Y.</creatorcontrib><description>Aliment Pharmacol Ther 2010; 32: 1059–1068
Summary
Background The long‐term benefit of interferon‐alfa (IFN‐α) treatment in preventing various hepatic complications is not certain.
Aim To study the effects of IFN‐α on reducing the risk of developing overall hepatic events (hepatocellular carcinoma, cirrhotic complications and liver‐related mortality) in chronic hepatitis B patients.
Methods Randomized controlled trials, case–control studies and cohort studies were retrieved from electronic databases and conference s. Relative risks (RRs) of different hepatic complications among patients treated by IFN‐α vs. no treatment or placebo were studied.
Results Eleven studies were identified totalling 975 patients treated by IFN‐α vs. 1147 untreated controls for analysis. Patients were treated by IFN‐α for 1–24 months with a post‐treatment follow‐up of 1–13 years. Treatment by IFN‐α reduced the risk of overall hepatic events (RR 0.55, 95% confident interval or CI 0.43–0.70, P < 0.001) and cirrhotic complications (RR 0.46, 95% CI 0.32–0.67, P < 0.001) by 45% and 54% respectively. Patients who responded to IFN‐α had more profound reduction in overall hepatic events (RR 0.20, 95% CI 0.05–0.87, P = 0.03) and cirrhotic complications (RR 0.19, 95% CI 0.09–0.38, P < 0.001) vs. the untreated controls.
Conclusion Interferon‐alfa treatment reduces the risk of hepatic events particularly among responders to treatment.</description><identifier>ISSN: 0269-2813</identifier><identifier>EISSN: 1365-2036</identifier><identifier>DOI: 10.1111/j.1365-2036.2010.04447.x</identifier><identifier>PMID: 20807216</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>alpha -Interferon ; Biological and medical sciences ; Carcinoma, Hepatocellular - etiology ; Carcinoma, Hepatocellular - prevention & control ; Clinical trials ; Conferences ; Digestive system ; Gastroenterology. Liver. Pancreas. Abdomen ; Hepatitis B ; Hepatitis B, Chronic - complications ; Hepatitis B, Chronic - drug therapy ; Hepatitis B, Chronic - pathology ; Hepatocellular carcinoma ; Human viral diseases ; Humans ; Infectious diseases ; Interferon-alpha - therapeutic use ; Liver Neoplasms - prevention & control ; Medical sciences ; Mortality ; Pharmacology. Drug treatments ; Randomized Controlled Trials as Topic ; Reviews ; Risk assessment ; Statistics as Topic ; Treatment Outcome ; Viral diseases ; Viral hepatitis</subject><ispartof>Alimentary pharmacology & therapeutics, 2010-11, Vol.32 (9), p.1059-1068</ispartof><rights>2010 Blackwell Publishing Ltd</rights><rights>2015 INIST-CNRS</rights><rights>2010 Blackwell Publishing Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4307-b869ad6259c0127779f1e1a3d1240dbed270f5a18feca3dadb3883247a141b773</citedby><cites>FETCH-LOGICAL-c4307-b869ad6259c0127779f1e1a3d1240dbed270f5a18feca3dadb3883247a141b773</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=23288528$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20807216$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wong, G. L.‐H.</creatorcontrib><creatorcontrib>Yiu, K. K.‐L.</creatorcontrib><creatorcontrib>Wong, V. W.‐S.</creatorcontrib><creatorcontrib>Tsoi, K. K.‐F.</creatorcontrib><creatorcontrib>Chan, H. L.‐Y.</creatorcontrib><title>Meta‐analysis: reduction in hepatic events following interferon‐alfa therapy of chronic hepatitis B</title><title>Alimentary pharmacology & therapeutics</title><addtitle>Aliment Pharmacol Ther</addtitle><description>Aliment Pharmacol Ther 2010; 32: 1059–1068
Summary
Background The long‐term benefit of interferon‐alfa (IFN‐α) treatment in preventing various hepatic complications is not certain.
Aim To study the effects of IFN‐α on reducing the risk of developing overall hepatic events (hepatocellular carcinoma, cirrhotic complications and liver‐related mortality) in chronic hepatitis B patients.
Methods Randomized controlled trials, case–control studies and cohort studies were retrieved from electronic databases and conference s. Relative risks (RRs) of different hepatic complications among patients treated by IFN‐α vs. no treatment or placebo were studied.
Results Eleven studies were identified totalling 975 patients treated by IFN‐α vs. 1147 untreated controls for analysis. Patients were treated by IFN‐α for 1–24 months with a post‐treatment follow‐up of 1–13 years. Treatment by IFN‐α reduced the risk of overall hepatic events (RR 0.55, 95% confident interval or CI 0.43–0.70, P < 0.001) and cirrhotic complications (RR 0.46, 95% CI 0.32–0.67, P < 0.001) by 45% and 54% respectively. Patients who responded to IFN‐α had more profound reduction in overall hepatic events (RR 0.20, 95% CI 0.05–0.87, P = 0.03) and cirrhotic complications (RR 0.19, 95% CI 0.09–0.38, P < 0.001) vs. the untreated controls.
Conclusion Interferon‐alfa treatment reduces the risk of hepatic events particularly among responders to treatment.</description><subject>alpha -Interferon</subject><subject>Biological and medical sciences</subject><subject>Carcinoma, Hepatocellular - etiology</subject><subject>Carcinoma, Hepatocellular - prevention & control</subject><subject>Clinical trials</subject><subject>Conferences</subject><subject>Digestive system</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Hepatitis B</subject><subject>Hepatitis B, Chronic - complications</subject><subject>Hepatitis B, Chronic - drug therapy</subject><subject>Hepatitis B, Chronic - pathology</subject><subject>Hepatocellular carcinoma</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>Infectious diseases</subject><subject>Interferon-alpha - therapeutic use</subject><subject>Liver Neoplasms - prevention & control</subject><subject>Medical sciences</subject><subject>Mortality</subject><subject>Pharmacology. Drug treatments</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Reviews</subject><subject>Risk assessment</subject><subject>Statistics as Topic</subject><subject>Treatment Outcome</subject><subject>Viral diseases</subject><subject>Viral hepatitis</subject><issn>0269-2813</issn><issn>1365-2036</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><recordid>eNqNkcFOGzEURa2qqATaX6i8QV1N-mzP2E6lLigqFAlEF3RteTzPxNFkJtiTQnb9BL6RL8FDAt3ija37zrWtewmhDKYsr6-LKROyKjgIOeWQVSjLUk3v35HJ6-A9mQCXs4JrJvbJQUoLAJAK-Aeyz0GD4kxOyM0lDvbx34PtbLtJIX2jEZu1G0Lf0dDROa7sEBzFv9gNifq-bfu70N3k2YDRY-y70dx6S4c5Rrva0N5TN896dm3dQ0j0x0ey522b8NNuPyR_Tn9en_wqLq7Ozk-OLwpXClBFreXMNpJXMweMK6VmniGzomG8hKbGhivwlWXao8uqbWqhteClsqxktVLikHzZ3ruK_e0a02CWITlsW9thv05GSc51VbHqbSTjEjKpt6SLfUoRvVnFsLRxYxiYsQ-zMGPsZozdjH2Y5z7MfbZ-3j2yrpfYvBpfCsjA0Q6wyeUco-1cSP85wbWuuM7c9y13F1rcvPkD5vj39XgST76BqHY</recordid><startdate>201011</startdate><enddate>201011</enddate><creator>Wong, G. L.‐H.</creator><creator>Yiu, K. K.‐L.</creator><creator>Wong, V. W.‐S.</creator><creator>Tsoi, K. K.‐F.</creator><creator>Chan, H. L.‐Y.</creator><general>Blackwell Publishing Ltd</general><general>Blackwell</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7U7</scope><scope>7U9</scope><scope>C1K</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>201011</creationdate><title>Meta‐analysis: reduction in hepatic events following interferon‐alfa therapy of chronic hepatitis B</title><author>Wong, G. L.‐H. ; Yiu, K. K.‐L. ; Wong, V. W.‐S. ; Tsoi, K. K.‐F. ; Chan, H. L.‐Y.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4307-b869ad6259c0127779f1e1a3d1240dbed270f5a18feca3dadb3883247a141b773</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>alpha -Interferon</topic><topic>Biological and medical sciences</topic><topic>Carcinoma, Hepatocellular - etiology</topic><topic>Carcinoma, Hepatocellular - prevention & control</topic><topic>Clinical trials</topic><topic>Conferences</topic><topic>Digestive system</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Hepatitis B</topic><topic>Hepatitis B, Chronic - complications</topic><topic>Hepatitis B, Chronic - drug therapy</topic><topic>Hepatitis B, Chronic - pathology</topic><topic>Hepatocellular carcinoma</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>Infectious diseases</topic><topic>Interferon-alpha - therapeutic use</topic><topic>Liver Neoplasms - prevention & control</topic><topic>Medical sciences</topic><topic>Mortality</topic><topic>Pharmacology. Drug treatments</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Reviews</topic><topic>Risk assessment</topic><topic>Statistics as Topic</topic><topic>Treatment Outcome</topic><topic>Viral diseases</topic><topic>Viral hepatitis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wong, G. L.‐H.</creatorcontrib><creatorcontrib>Yiu, K. K.‐L.</creatorcontrib><creatorcontrib>Wong, V. W.‐S.</creatorcontrib><creatorcontrib>Tsoi, K. K.‐F.</creatorcontrib><creatorcontrib>Chan, H. L.‐Y.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Alimentary pharmacology & therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wong, G. L.‐H.</au><au>Yiu, K. K.‐L.</au><au>Wong, V. W.‐S.</au><au>Tsoi, K. K.‐F.</au><au>Chan, H. L.‐Y.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Meta‐analysis: reduction in hepatic events following interferon‐alfa therapy of chronic hepatitis B</atitle><jtitle>Alimentary pharmacology & therapeutics</jtitle><addtitle>Aliment Pharmacol Ther</addtitle><date>2010-11</date><risdate>2010</risdate><volume>32</volume><issue>9</issue><spage>1059</spage><epage>1068</epage><pages>1059-1068</pages><issn>0269-2813</issn><eissn>1365-2036</eissn><abstract>Aliment Pharmacol Ther 2010; 32: 1059–1068
Summary
Background The long‐term benefit of interferon‐alfa (IFN‐α) treatment in preventing various hepatic complications is not certain.
Aim To study the effects of IFN‐α on reducing the risk of developing overall hepatic events (hepatocellular carcinoma, cirrhotic complications and liver‐related mortality) in chronic hepatitis B patients.
Methods Randomized controlled trials, case–control studies and cohort studies were retrieved from electronic databases and conference s. Relative risks (RRs) of different hepatic complications among patients treated by IFN‐α vs. no treatment or placebo were studied.
Results Eleven studies were identified totalling 975 patients treated by IFN‐α vs. 1147 untreated controls for analysis. Patients were treated by IFN‐α for 1–24 months with a post‐treatment follow‐up of 1–13 years. Treatment by IFN‐α reduced the risk of overall hepatic events (RR 0.55, 95% confident interval or CI 0.43–0.70, P < 0.001) and cirrhotic complications (RR 0.46, 95% CI 0.32–0.67, P < 0.001) by 45% and 54% respectively. Patients who responded to IFN‐α had more profound reduction in overall hepatic events (RR 0.20, 95% CI 0.05–0.87, P = 0.03) and cirrhotic complications (RR 0.19, 95% CI 0.09–0.38, P < 0.001) vs. the untreated controls.
Conclusion Interferon‐alfa treatment reduces the risk of hepatic events particularly among responders to treatment.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>20807216</pmid><doi>10.1111/j.1365-2036.2010.04447.x</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0269-2813 |
| ispartof | Alimentary pharmacology & therapeutics, 2010-11, Vol.32 (9), p.1059-1068 |
| issn | 0269-2813 1365-2036 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_762285515 |
| source | Wiley-Blackwell Read & Publish Collection |
| subjects | alpha -Interferon Biological and medical sciences Carcinoma, Hepatocellular - etiology Carcinoma, Hepatocellular - prevention & control Clinical trials Conferences Digestive system Gastroenterology. Liver. Pancreas. Abdomen Hepatitis B Hepatitis B, Chronic - complications Hepatitis B, Chronic - drug therapy Hepatitis B, Chronic - pathology Hepatocellular carcinoma Human viral diseases Humans Infectious diseases Interferon-alpha - therapeutic use Liver Neoplasms - prevention & control Medical sciences Mortality Pharmacology. Drug treatments Randomized Controlled Trials as Topic Reviews Risk assessment Statistics as Topic Treatment Outcome Viral diseases Viral hepatitis |
| title | Meta‐analysis: reduction in hepatic events following interferon‐alfa therapy of chronic hepatitis B |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T01%3A28%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Meta%E2%80%90analysis:%20reduction%20in%20hepatic%20events%20following%20interferon%E2%80%90alfa%20therapy%20of%20chronic%20hepatitis%20B&rft.jtitle=Alimentary%20pharmacology%20&%20therapeutics&rft.au=Wong,%20G.%20L.%E2%80%90H.&rft.date=2010-11&rft.volume=32&rft.issue=9&rft.spage=1059&rft.epage=1068&rft.pages=1059-1068&rft.issn=0269-2813&rft.eissn=1365-2036&rft_id=info:doi/10.1111/j.1365-2036.2010.04447.x&rft_dat=%3Cproquest_cross%3E762285515%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4307-b869ad6259c0127779f1e1a3d1240dbed270f5a18feca3dadb3883247a141b773%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=762281260&rft_id=info:pmid/20807216&rfr_iscdi=true |